Amendment: Labelling for unauthorised investigational medicinal products

This regulation updates the rules for how labels must be designed and applied to medicines used in clinical trials. It ensures that unauthorized investigational products and their auxiliary medicines are clearly identified, which is critical for patient safety and the integrity of medical research.

This affects pharmaceutical companies, clinical research organizations, and healthcare providers conducting human clinical trials within the EU.